BiotechTube

RAD001, everolimus

Phase 2Terminated
0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neurofibromatosis Type 2

Conditions

Neurofibromatosis Type 2, Neuroma, Acoustic

Trial Timeline

Jul 1, 2015 → Feb 6, 2024

NCT ID
NCT01345136

About RAD001, everolimus

RAD001, everolimus is a phase 2 stage product being developed by Novartis for Neurofibromatosis Type 2. The current trial status is terminated. This product is registered under clinical trial identifier NCT01345136. Target conditions include Neurofibromatosis Type 2, Neuroma, Acoustic.

What happened to similar drugs?

0 of 1 similar drugs in Neurofibromatosis Type 2 were approved

Approved (0) Terminated (0) Active (1)
🔄SelumetinibAstraZenecaPhase 3

Hype Score Breakdown

Clinical
12
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01345136Phase 2Terminated

Competing Products

20 competing products in Neurofibromatosis Type 2

See all competitors
ProductCompanyStageHype Score
SelumetinibAstraZenecaPhase 2
27
SelumetinibAstraZenecaPhase 1
33
SelumetinibAstraZenecaPhase 1
29
AZD2014AstraZenecaPhase 2
35
Selumetinib + PlaceboAstraZenecaPhase 2
27
Treatment A + Treatment B + Treatment C + Treatment D + AcetaminophenAstraZenecaPhase 1
29
SelumetinibAstraZenecaPhase 1/2
32
SelumetinibAstraZenecaPhase 1
33
Selumetinib granule formulation + Selumetinib capsule formulationAstraZenecaPhase 1/2
36
SelumetinibAstraZenecaPhase 3
44
Everolimus (RAD001) , Afinitor®NovartisPhase 2
35
RAD001: EverolimusNovartisPhase 2
35
TasignaNovartisPhase 1
29
TrametinibNovartisPhase 2
39
Everolimus (RAD001)NovartisPhase 2
27
Sutent®/SunitinibPfizerPhase 2
27
Sorafenib (Nexavar)BayerPhase 2
24
PTC299United TherapeuticsPhase 2
24
REC-2282 + PlaceboRecursion PharmaceuticalsPhase 2/3
24
BinimetinibPacific BiosciencesPhase 2
25